Statins: can the new generation make an impression?

Bibliography

• KULLER LH, WENTWORTH D: Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet (1986) 2:933–936.
   PubMed Web of Science ®Google Scholar
• STAMLER J, WENTWORTH D, NEATON JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA (1986) 256:2823–2828.
   PubMed Web of Science ®Google Scholar
• VERSCHUREN WM, JACOBS DR, BLOEMBERG BP et al.: Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA (1995) 274:131–136.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al FOR THE WEST OF SCOTLAND CORONARY PREVENTION STUDY GROUP: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl.' Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA (1998) 279:1615–1622.
   PubMed Web of Science ®Google Scholar
• THE LONG-TERM INTERVENTIONWITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al.: ASCOT INVESTIGATORS: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361:1149–1158.
   PubMed Web of Science ®Google Scholar
• WOOD D, DE BACKER G, FAERGEMAN O, GRAHAM I, MANCIA G, PYORALA K: Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart" (1998) 19:1434–1503.
   PubMed Web of Science ®Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). "AMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, MCCABE CH et al.: PRAVASTATIN OR ATORVASTATIN EVALUATION AND INFECTION THERAPY-THROMBOLYSIS IN MYOCARDIAL INFARCTION 22 INVESTIGATORS: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350:1495–1504.
   PubMed Web of Science ®Google Scholar
• ••A head-to-head statin trial demonstratinggreater protection against cardiovascular events following intensive lipid lowering compared with a moderate regimen.
   Google Scholar
• BALLANTYNE CM: Low-density lipoproteins and risk for coronary artery disease. Am.! Cardiol. (1998) 82:3Q–12Q.
   Google Scholar
• NISSEN SE, TUZCU EM,SCHOENHAGEN P et al.: REVERSAL INVESTIGATORS: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 291:1071–1080.
   PubMed Web of Science ®Google Scholar
• ••A head-to-head statin trial demonstrating that intensive lipid lowering reduces atherosclerosis progression compared with a moderate regimen.
   Google Scholar
• COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al, CARDS INVESTIGATORS: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364:685–696.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, CLEEMAN JI, MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation (2004) 110:227–239.
   PubMed Web of Science ®Google Scholar
• DE BACKER G, AMBROSIONI E, BORCH-JOHNSEN K et al.: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart" (2003) 24:1601–1610.
   PubMed Web of Science ®Google Scholar
• FEDDER DO, KORO CE, LITALIEN GJ: New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy. Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation (2002) 105:152–156.
   PubMed Web of Science ®Google Scholar
• ITO MK, DELUCCA GM, ALDRIDGE MA: The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J. Cardiovasc. Pharmacol. Ther. (2001) 6:129–135.
   PubMedGoogle Scholar
• ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr: Med. Res. Opin. (2002) 18:499–502.
   PubMed Web of Science ®Google Scholar
• PEARSON TA, LAURORA I, CHU H, KAFONEK S: The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. (2000) 160:459–467.
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II STUDY GROUP: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Ear: Heart j (2001) 22: 554–572.
   PubMed Web of Science ®Google Scholar
• CLEARFIELD MB: Statins: balancing benefits, efficacy and safety. Expert Opin. Pharmacother. (2002) 3:469–477.
   PubMedGoogle Scholar
• IGEL M, SUDHOP T, VON BERGMANN K: Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. Clin. Pharmacol. (2002) 42:835–845.
   Google Scholar
• JONES P, KAFONEK S, LAURORA I, HUNNINGHAKE D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. (1998) 81:582–587.
   PubMed Web of Science ®Google Scholar
• JONES PH, DAVIDSON MH, STEIN EA et al.: FOR THE STELLAR STUDY GROUP: Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. I Cardiol. (2003) 92:152–160.
   PubMed Web of Science ®Google Scholar
• •A key comparative study assessing the effects of rosuvastatin, atorvastatin, simvastatin and pravastatin across their dose ranges.
   Google Scholar
• OLSSON AG, PAUCIULLO P, SOSKA V et al.: Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin. Ther. (2001) 23:45–61.
   PubMed Web of Science ®Google Scholar
• KAJINAMI K, TAKEKOSHI N, SAITO Y: Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev (2003) 21:199–215.
   PubMed Web of Science ®Google Scholar
• ••A review of available data regarding theefficacy and safety of pitavastatin.
   Google Scholar
• SAITO Y, YAMADA N, TERAMOTO T et al.: A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis (2002) 162:373–379.
   PubMed Web of Science ®Google Scholar
• •A key comparative study assessing the effects of pitavastatin and pravastatin.
   Google Scholar
• BLASETTO JVV, STEIN EA, BROWN WV, CHITRA R, RAZA A: Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in specialpopulation groups. Am. j Cardiol (2003) 91:3C–10C.
   Google Scholar
• OLSSON AG, ISTAD H, LUURILA 0 et al.: ROSUVASTATIN INVESTIGATORS GROUP: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am. Heart J. (2002) 144:1044–1051.
   PubMed Web of Science ®Google Scholar
• DAVIDSON M, MAP, STEIN EA et al.: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with Type IIa or IIb hypercholesterolemia. Am. Cardiol(2002) 89:268–275.
   PubMed Web of Science ®Google Scholar
• BROWN WV, BAYS HE, HASSMAN DR et al.: ROSUVASTATIN STUDY GROUP: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Jim. Heart J.(2002) 144:1036–1043.
   PubMed Web of Science ®Google Scholar
• PAOLETTI R, FAHMY M, MAHLA G, MIZAN J, SOUTHVVORTH H: Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study..1 Cardiovasc. Risk (2001) 8:383–390.
   PubMedGoogle Scholar
• MCKENNEY JM, JONES PH, ADAMCZYK MA, CAIN VA, BRYZINSKI BS, BLASETTO JW; FOR THE STELLAR STUDY GROUP: Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals (results from the STELLAR trial). Curr. Med. Res. Opin. (2003) 19:689–698.
   PubMed Web of Science ®Google Scholar
• SCHUSTER H, BARTER PJ,STENDER S et al.: FOR THE MERCURY I STUDY GROUP: Effects of switching statins on achievement of lipid goal: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am. Heart J. (2004) 147:705–712.
   PubMed Web of Science ®Google Scholar
• KRITHARIDES L: Reducing low-density lipoprotein cholesterol - treating to target and meeting new European goals. Eur. Heart J. Sapp]. (2004) 6(Suppl. A): Al2–A18.
   Google Scholar
• SCHUSTER H, FOX JC: Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme'. Expert Opin. Pbarmacother. (2004) 5:1187–1200.
   PubMed Web of Science ®Google Scholar
• BETTERIDGE D, GIBSON M: Effect ofrosuvastatin and atorvastatin on LDL-C and CRP levels in patients with Type 2 diabetes: results of the ANDROMEDA study. Atheroscler. Suppl (2004) 5:107.
   PubMed Web of Science ®Google Scholar
• ASSMANN G, SCHULTE H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am. J. Cardiol (1992) 70:733–737.
   Web of Science ®Google Scholar
• HODIS HN, MACK WJ: Triglyceride-richlipoproteins and progression of atherosclerosis. Eur. Heart J. (1998)19 (Suppl. A):A40–A44.
   Google Scholar
• WALLDIUS G, JUNGNER I, HOLME I, AASTVEIT AH, KOLAR W, STEINER E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet (2001) 358:2026–2033.
   PubMed Web of Science ®Google Scholar
• RADER DJ, DAVIDSON MH, CAPLAN RI, PEARS JS: Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am. J. Cardiol (2003) 91:20C–24C.
   Google Scholar
• BREWER HB JR: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol (2003) 92(Suppl.):23K–29K.
   Google Scholar
• ROSENSON RS: Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc. Ther. (2003) 1:495–505.
   PubMedGoogle Scholar
• ••A comprehensive review of the efficacy andsafety of rosuvastatin in major clinical trials.
   Google Scholar
• SCHUSTERH: Rosuvastatin - a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg in dyslipidemia patients. Cardiology (2003) 99:126–139.
   PubMed Web of Science ®Google Scholar
• ROSENSON RS: Current overview of statin-induced myopathy. Am. J. Med. (2004) 116:408–416.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of clinicalcharacteristics that identify patients at high risk for statin-associated myopathy. This article presents a mechanistic basis for the pharmacological differences in myotoxicity amongst statins, and new information on drug interactions.
   Google Scholar
• VIDT DG, CRESSMAN MD, HARRIS S, PEARS JS, HUTCHINSON HG: Rosuvastatin-induced arrest in progression of renal disease. Cardiology (2004) 102:52–60.
   PubMed Web of Science ®Google Scholar
• SAITO Y, GOTO Y, DANE A, STRUTT K, RAZA A: Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.J. Atheroscler: Thromb. (2003) 10:329–336.
   PubMedGoogle Scholar
• FERDINAND K, DEEDWANIA PC, HAFFNER S, CAPLAN RI, GOLD A: Designs of 3 trials comparing rosuvastatin and atorvastatin in African American, South Asian and Hispanic patients: ARIES, IRIS and STARSHIP trials. Atheroscler. Sapp]. (2003) 4:83.
   Web of Science ®Google Scholar
• TERAMOTO T, SAITO Y, NAKAYA N: Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidaemia. Atherosclerosis (2000) 151:53.
   Google Scholar
• ROSENSON RS, BROWN AS: Statin usein acute coronary syndromes: cellular mechanisms and clinical evidence. Curc Opin. Lipidol (2002) 13:625–630.
   PubMed Web of Science ®Google Scholar
• DURRINGTON PN, TUOMILEHTO J, HAMANN A, KALLEND D, SMITH K: Rosuvastatin and fenofibrate alone and in combination in Type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res. Clin. Pract. (2004) 64:137–151.
   PubMed Web of Science ®Google Scholar
• LAUFS U, GERTZ K, DIRNAGL U, BOHM M, NICKENIG G, ENDRES M: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. (2002)942:23–30.
   PubMed Web of Science ®Google Scholar
• FELLSTROM B, ZANNAD F, SCHMIEDER R et al.: A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events - the AURORA study. Nepbrol. Dial. Transplant. (2003) 18 (Suppl. 4):713.
   Google Scholar
• TAVAZZI L, TOGNONI G,FRANZOSI MG et al.: ON BEHALF OF GISSI-HF INVESTIGATORS: Rationale and design of the GISSI Heart Failure Trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure.Eur: J. Heart Fail (2004) 6:635–641.
   PubMed Web of Science ®Google Scholar
• RIDKER PM; ON BEHALF OF THE JUPITER STUDY GROUP: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low LDL cholesterol and elevated high sensitivity C-reactive protein (hsCRP). Circulation (2003) 108:2292–2297.
   PubMed Web of Science ®Google Scholar
• KLINGMAN D, WILLIAMS S, SMITH T, AHN J, PRASAD C, O'DONNELL J: Correlates of elevated c-reactive protein among adults in the United States: Findings from the 1999–2000 National Health and Nutrition aExamination Survey. I Am. Coll. Cardiol (2004) 43(Suppl. A):475A.
   Google Scholar
• RIDKER PM, RIFAI N, CLEARFIELD M et al.: AIR FORCE/TEXAS CORONARY ATHEROSCLEROSIS PREVENTION STUDY INVESTIGATORS: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Eng1.1. Med. (2001) 344:1959–1965.
   Google Scholar